CELU Celularity Inc

Nasdaq celularity.com


$ 1.70 $ 0.00 (0 %)    

Tuesday, 04-Nov-2025 15:58:48 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 1.72
$ 1.73
$ 1.59 x 125
$ 1.91 x 1,600
$ 1.62 - $ 1.74
$ 1.00 - $ 5.22
67,161
na
45.91M
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-29-2025 06-30-2025 10-Q
2 08-29-2025 03-31-2025 10-Q
3 05-08-2025 12-31-2024 10-K
4 12-06-2024 09-30-2024 10-Q
5 11-06-2024 06-30-2024 10-Q
6 10-16-2024 03-31-2024 10-Q
7 07-30-2024 12-31-2023 10-K
8 01-03-2024 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-22-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-19-2021 06-30-2021 10-Q
18 05-24-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-24-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 celularity-enters-strategic-partnership-with-defeye-including-an-exclusive-license-and-pricing-agreement-tied-to-celularitys-in-kind-investment-in-defeyes-12m-series-seed-preferred-equity-funding-round

Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and d...

 celularity-files-for-6m-series-a-convertible-preferred-stock-raising-up-to-667m-in-private-placement-with-warrants

Private Placement Transaction On October 24, 2025, Celularity Inc. (the "Company") entered into a Securities Purchase A...

 celularity-announces-publication-of-its-phase-2-study-on-pda-002-demonstrating-safety-and-efficacy-in-treating-complex-diabetic-wounds

Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and d...

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

 wbb-securities-upgrades-celularity-to-buy-maintains-price-target-to-6

WBB Securities analyst Steve Brozak upgrades Celularity (NASDAQ:CELU) from Hold to Buy and maintains the price target from $...

 wbb-securities-initiates-coverage-on-celularity-with-speculative-buy-rating-announces-price-target-of-6

WBB Securities analyst Steve Brozak initiates coverage on Celularity (NASDAQ:CELU) with a Speculative Buy rating and announc...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION